Literature DB >> 18467655

Macrophages define the invasive microenvironment in breast cancer.

Jeffrey W Pollard1.   

Abstract

In many human cancers, the abundance of macrophages in the tumor microenvironment is correlated with poor prognosis. Experimental evidence for the causal relationship between macrophages and poor prognosis came from mouse models of breast cancer in which genetic ablation of macrophages resulted in attenuation of tumor progression and metastasis, and premature recruitment to hyperplastic lesions accelerated these processes. Malignancy is defined by the invasion of tumor cells into the stroma, a process that allows escape of these cells into the circulation and dissemination to distant sites. In this review, I argue that macrophages are recruited to the invasive front by expression of tumor-derived chemotactic factors and in response to the disruption of the basement membrane. At this invasive site, macrophages enhance tumor cell migration and invasion through their secretion of chemotactic and chemokinetic factors including epidermal growth factor (EGF). They promote angiogenesis by the synthesis of angiogenic factors including vascular endothelial growth factor (VEGF), and they remodel the extracellular matrix and in particular, regulate collagen fibrillogenesis. A combination of these factors provides a triple-whammy, as the more mobile and invasive tumor cells track along collagen fibers that are also anchored to blood vessels, which are fabricated at sites of invasion and through which macrophages potentiate tumor cell intravasation. All of these activities suggest that macrophage functions are significant targets for the generation of novel therapeutics that should improve the current cytotoxic armamentarium.

Entities:  

Mesh:

Year:  2008        PMID: 18467655      PMCID: PMC2516896          DOI: 10.1189/jlb.1107762

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  70 in total

1.  VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells.

Authors:  Myriam Grunewald; Inbal Avraham; Yuval Dor; Esther Bachar-Lustig; Ahuva Itin; Steffen Jung; Steffen Yung; Stephano Chimenti; Limor Landsman; Rinat Abramovitch; Eli Keshet
Journal:  Cell       Date:  2006-01-13       Impact factor: 41.582

Review 2.  Macrophages: obligate partners for tumor cell migration, invasion, and metastasis.

Authors:  John Condeelis; Jeffrey W Pollard
Journal:  Cell       Date:  2006-01-27       Impact factor: 41.582

Review 3.  Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression.

Authors:  Paolo Serafini; Ivan Borrello; Vincenzo Bronte
Journal:  Semin Cancer Biol       Date:  2005-09-15       Impact factor: 15.707

Review 4.  Distinct role of macrophages in different tumor microenvironments.

Authors:  Claire E Lewis; Jeffrey W Pollard
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

5.  Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host.

Authors:  Bo Huang; Ping-Ying Pan; Qingsheng Li; Alice I Sato; David E Levy; Jonathan Bromberg; Celia M Divino; Shu-Hsia Chen
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

6.  Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis.

Authors:  Li Yang; Jianhua Huang; Xiubao Ren; Agnieszka E Gorska; Anna Chytil; Mary Aakre; David P Carbone; Lynn M Matrisian; Ann Richmond; P Charles Lin; Harold L Moses
Journal:  Cancer Cell       Date:  2008-01       Impact factor: 31.743

7.  A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis.

Authors:  Susanna Lewēn; He Zhou; Huai-dong Hu; Tingmei Cheng; Dorothy Markowitz; Ralph A Reisfeld; Rong Xiang; Yunping Luo
Journal:  Cancer Immunol Immunother       Date:  2007-09-05       Impact factor: 6.968

8.  Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors.

Authors:  Jeffrey B Wyckoff; Yarong Wang; Elaine Y Lin; Jiu-feng Li; Sumanta Goswami; E Richard Stanley; Jeffrey E Segall; Jeffrey W Pollard; John Condeelis
Journal:  Cancer Res       Date:  2007-03-15       Impact factor: 12.701

9.  Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors.

Authors:  Michele De Palma; Mary Anna Venneri; Rossella Galli; Lucia Sergi Sergi; Letterio S Politi; Maurilio Sampaolesi; Luigi Naldini
Journal:  Cancer Cell       Date:  2005-09       Impact factor: 31.743

10.  High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer.

Authors:  D-W Kim; H S Min; K-H Lee; Y J Kim; D-Y Oh; Y K Jeon; S-H Lee; S-A Im; D H Chung; Y T Kim; T-Y Kim; Y-J Bang; S W Sung; J H Kim; D S Heo
Journal:  Br J Cancer       Date:  2008-02-19       Impact factor: 7.640

View more
  194 in total

1.  High expression of tumor-infiltrating macrophages correlates with poor prognosis in patients with diffuse large B-cell lymphoma.

Authors:  Qi-chun Cai; Hong Liao; Su-xia Lin; Yi Xia; Xiao-xaio Wang; Yan Gao; Ze-xiao Lin; Jia-bin Lu; Hui-qiang Huang
Journal:  Med Oncol       Date:  2011-12-24       Impact factor: 3.064

Review 2.  Treating metastatic cancer with nanotechnology.

Authors:  Avi Schroeder; Daniel A Heller; Monte M Winslow; James E Dahlman; George W Pratt; Robert Langer; Tyler Jacks; Daniel G Anderson
Journal:  Nat Rev Cancer       Date:  2011-12-23       Impact factor: 60.716

Review 3.  Targeted complement inhibition and microvasculature in transplants: a therapeutic perspective.

Authors:  M A Khan; J L Hsu; A M Assiri; D C Broering
Journal:  Clin Exp Immunol       Date:  2015-11-05       Impact factor: 4.330

4.  Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Postmenopausal Women.

Authors:  Carol J Fabian; Bruce F Kimler; Teresa A Phillips; Jennifer L Nydegger; Amy L Kreutzjans; Susan E Carlson; Brandon H Hidaka; Trina Metheny; Carola M Zalles; Gordon B Mills; Kandy R Powers; Debra K Sullivan; Brian K Petroff; Whitney L Hensing; Brooke L Fridley; Stephen D Hursting
Journal:  Cancer Prev Res (Phila)       Date:  2015-08-14

Review 5.  Microbiome, bile acids, and obesity: How microbially modified metabolites shape anti-tumor immunity.

Authors:  Laura M Sipe; Mehdi Chaib; Ajeeth K Pingili; Joseph F Pierre; Liza Makowski
Journal:  Immunol Rev       Date:  2020-05       Impact factor: 12.988

6.  Comparison of breast and abdominal adipose tissue mesenchymal stromal/stem cells in support of proliferation of breast cancer cells.

Authors:  Jaehyup Kim; Leah E Escalante; Bridget A Dollar; Summer E Hanson; Peiman Hematti
Journal:  Cancer Invest       Date:  2013-09-10       Impact factor: 2.176

7.  The impact of expressions of CD97 and its ligand CD55 at the invasion front on prognosis of rectal adenocarcinoma.

Authors:  Shao-Liang Han; Chang Xu; Xiu-Ling Wu; Jun-Lin Li; Zhi Liu; Qi-Qiang Zeng
Journal:  Int J Colorectal Dis       Date:  2010-03-26       Impact factor: 2.571

8.  Early TGF-β inhibition in mice reduces the incidence of breast cancer induced bone disease in a myeloid dependent manner.

Authors:  Denise Buenrostro; Kristin A Kwakwa; Nicole E Putnam; Alyssa R Merkel; Joshua R Johnson; James E Cassat; Julie A Sterling
Journal:  Bone       Date:  2018-05-16       Impact factor: 4.398

9.  Effect of nitric oxide on the anticancer activity of the topoisomerase-active drugs etoposide and adriamycin in human melanoma cells.

Authors:  Birandra K Sinha; Ashutosh Kumar; Suchandra Bhattacharjee; Michael G Espey; Ronald P Mason
Journal:  J Pharmacol Exp Ther       Date:  2013-09-18       Impact factor: 4.030

Review 10.  The potential for genetically altered microglia to influence glioma treatment.

Authors:  W Li; R M D Holsinger; C A Kruse; A Flügel; M B Graeber
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-09       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.